Senzar Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Senzar Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-364,000	Closed	-$4.56M	–	30
2016 Q4	$4.56M	Buy	+364,000	New	+$4.33M	1.21%	20
2016 Q3	–	Sell	-219,743	Closed	-$2.17M	–	42
2016 Q2	$2.17M	Buy	+219,743	New	+$3.64M	0.47%	39
2016 Q1	–	Sell	-223,700	Closed	-$4.98M	–	43
2015 Q4	$4.98M	Buy	+223,700	New	+$5.64M	0.55%	33
2015 Q3	–	Sell	-153,900	Closed	-$12.6M	–	38
2015 Q2	$12.6M	Buy	+153,900	New	+$15.1M	2.16%	13

Other funds holding ESPR

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Senzar Asset Management's ESPR Position: Q1 2017 in Review

Senzar Asset Management sold out of Esperion Therapeutics (ESPR) in Q1 2017, closing a stake of 364,000 shares — an estimated $4.56M sold.

Senzar Asset Management first reported a position in ESPR in Q2 2015 and held it in 4 quarters. The position peaked at $12.6M in Q2 2015. 119 funds tracked by Wall St. Rank hold ESPR as of Q1 2017.

Senzar Asset Management reported no remaining Esperion Therapeutics position as of Q1 2017 after selling out during the quarter.
Senzar Asset Management sold 364,000 Esperion Therapeutics shares in Q1 2017, an estimated $4.56M.
Senzar Asset Management first reported a position in Esperion Therapeutics in Q2 2015 and held it in 4 quarters.
Senzar Asset Management's Esperion Therapeutics position peaked at $12.6M in Q2 2015.
119 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2017.

Based on Senzar Asset Management's 13F filing for Q1 2017, filed 12 May 2017.